University of Minnesota Kinase Degradation Compounds for Cancer Treatment
Summary
USPTO granted Patent US12605452B2 to the Regents of the University of Minnesota on April 21, 2026. The patent covers compounds of Formula (I) or (II) comprising Aurora A or CDK4/6 ligands linked to E3 ligase ligands, along with pharmaceutical compositions and methods for treating cancer using such compounds. The patent contains 13 claims.
What changed
USPTO granted Patent US12605452B2 to the Regents of the University of Minnesota for compounds that degrade kinases (Aurora A and CDK4/6 ligands) linked to E3 ligase ligands via a linker, and pharmaceutical compositions thereof. The patent also covers methods for treating cancer using these compounds.
Affected parties include the University of Minnesota, which now holds enforceable patent rights to these kinase degradation compounds, and potential licensees or researchers in the cancer therapeutics field who should reviewFreedom-to-Operate implications before developing similar compounds.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compounds that degrade kinases and uses thereof
Grant US12605452B2 Kind: B2 Apr 21, 2026
Assignee
Regents of the University of Minnesota
Inventors
Daniel A. Harki, Jian Tang, Ramkumar Moorthy, Rommie E. Amaro, Ozlem Demir
Abstract
The disclosure is directed to compounds of the Formula (I) or (II): A-L1-B, A′-L1-B, or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein A is an Aurora A ligand, A′ is a CDK4/6 ligand; B is an E3 ligase ligand; and L1 is a linker, as well as pharmaceutical compositions comprising such compounds, and methods for treating cancer using such compounds.
CPC Classifications
A61K 47/55 A61K 47/545 A61P 35/00 C07D 471/04 C07D 487/04 C07D 401/14
Filing Date
2020-06-03
Application No.
17615569
Claims
13
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.